Vnitr Lek 2016, 62(3):195-197

Victoza changes diabetes and lives of patients 5 years already

Jana Jiráčková1,2, Alena ©mahelová1,*
1 III. interní gerontometabolická klinika LF UK a FN Hradec Králové
2 Ústav klinické biochemie a diagnostiky LF UK a FN Hradec Králové

Victoza (liraglutide) is a modern antidiabetic drug of GLP1 (glucagone like peptide) analogue group; since 2009 registered in Czech republic. VICTOZA is used in therapy of type 2 diabetic patients with preserved endougenous insulin secretion, usually in combination with other peroral antidiabetic drugs or with basal insulin. VICTOZA is applied once a day subcutaneously. The characteristical antidiabetic effect with β cell protection is enhanced with supportive weigth reduction effect. Positive cardiovascular influence is expected, however data from recent studies are not available at this time. In clinical practice, the mild upper dyspepsia after initiation of therapy is the most common side effect, usually subsiding in several days. Alltogether, VICTOZA is a well tolerated antidiabetic medication decreasing glycated hemoglobin up to 15 mmol/l with minimal risk of hypoglycaemia.

Keywords: diabetes mellitus type 2; GLP1 analogue; incretine; liraglutide; Victoza

Received: February 29, 2016; Accepted: March 18, 2016; Published: March 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jiráčková J, ©mahelová A. Victoza changes diabetes and lives of patients 5 years already. Vnitr Lek. 2016;62(3):195-197.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Holst JJ. The Physiology of Glucagon-like Peptide 1. Physiol Rev 2007; 87(4): 1409-1439. Go to original source... Go to PubMed...
    2. SPC Victoza. Dostupné z WWW: <http://www.sukl.cz/modules/medication/detail.php?code=0149309&tab=texts>.
    3. Marre M, Shaw J, Brandle M et al. Liraglutide, a once daily human GLP-1 analogue, added to aulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26(3):268-278. Go to original source... Go to PubMed...
    4. Nauck M, Frid A, Hermansen K et al. Efficacy and safety comparison of liraglutide, glimepiride and placebo all in combination with metformin in type 2 diabetes: the LEAD-2study. Diabetes Care 2009; 32(1): 84-90. Go to original source... Go to PubMed...
    5. Garber A, Henry R, Ratner R et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised 52-week, phase III double-blind, parallel treatment trial. Lancet 2009; 37(9662): 473-481. Go to original source... Go to PubMed...
    6. Zinman B, Gerich J, Buse JB et al. Efficacy and safety of the humen glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidindione in patients with type 2 diabetes (LEAD-4 Met + TZD). Diabetes Care 2009; 32(7): 1224-1230. Erratum in Diabetes Care 2010; 33(3): 692. Go to original source... Go to PubMed...
    7. Russel JD, Vaag A, Schmitz O et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Diabetologia 2009; 52(10): 2046-2055. Go to original source... Go to PubMed...
    8. Buse JB, Rosenstock J, Sesti G et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised parallel-group, multinational, for type 2 diabetes: a 26-week randomised, parallel. Group, multinational, open. Label trial (LEAD-6). Lancet 2009; 374(9683): 39-47. Go to original source... Go to PubMed...
    9. Drucker DJ, Sherman SI, Gorelick FS et al. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 2010; 33(2): 428-433. Go to original source... Go to PubMed...
    10. Butler PC, Dry S, Elashoff R. GLP-1 based therapy for diabetes: what you do not know can hurt you. Diabetes Care 2010; 33(2): 453-455. Go to original source... Go to PubMed...
    11. Butler PC, Matveyenko AV, Dry S et al. Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire? Diabetologia 2010; 53(1): 1-6. Go to original source... Go to PubMed...
    12. Thomsen RW, Pedersen L, Moller N et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015; 38(6): 1089-1098. Go to original source... Go to PubMed...
    13. Jung MJ, Kwon SK. Expression of glucagon-like peptide-1 receptor in papillary thyroid carcinoma and its clinicopathologic significance. Endocrinol Metab (Seoul) 2014; 29(4): 536-544. Go to original source... Go to PubMed...
    14. Gier B, Butler PC, Lai CK et al. Glucagon like peptide-1 receptor expression in the human thyroid gland. J Clin Endocrinol Metab 2012; 97(1): 121-131. Go to original source... Go to PubMed...
    15. Sun F, Yu K, Wu S et al. Cardiovascular safety and glycemic control of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus: a pairwise and network meta-analysis. Diabetes Res Clin Pract 2012; 98(3): 386-395. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.